StreetInsider.com News Articles

Praxis Precision Medicines Inc. (PRAX) PT Raised to $575 at Goldman Sachs

Fri, 21 Aug 2026 06:29:03 -0400

Goldman Sachs analyst Kevin Strang raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $575.00 (from $470.00) while maintaining a Buy rating.

Praxis Precision Medicines Inc. (PRAX) PT Raised to $945 at Raymond James

Mon, 17 Aug 2026 06:15:52 -0400

Raymond James analyst Tiago Fauth raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $945.00 (from $765.00) while maintaining a Strong Buy rating.

The analyst comments "The next 6-12 months for Praxis represent one of the most compelling setups in SMID biotech. We think of it as a three-course dinner at the finest restaurant in town: relu’s Phase 3 EMERALD readout is the appetizer; ulixa’s PDUFA is the main course; ulixa’s launch in essential tremor is dessert. As appetizers often are, EMERALD is overlooked. We think that is primarily for two reasons: (1) investors understand the therapeutic hypothesis

Praxis Precision Medicines Inc. (PRAX) PT Raised to $945 at Raymond James

Mon, 17 Aug 2026 06:15:52 -0400

Raymond James analyst Tiago Fauth raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $945.00 (from $765.00) while maintaining a Strong Buy rating.

Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: ORBIS INVESTMENT MANAGEMENT LTD

Fri, 14 Aug 2026 14:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26928803.html

Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: ORBIS INVESTMENT MANAGEMENT LTD

Fri, 14 Aug 2026 14:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26928803.html

Praxis Precision Medicines Inc. (PRAX) PT Raised to $362 at Wells Fargo

Fri, 07 Aug 2026 08:20:33 -0400

Wells Fargo analyst Ben Burnett raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $362.00 (from $323.00) while maintaining a Equal Weight rating.

Praxis Precision Medicines Inc. (PRAX) PT Raised to $462 at RBC Capital

Fri, 07 Aug 2026 07:30:13 -0400

RBC Capital analyst Leonid Timashev raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $462.00 (from $449.00) while maintaining a Outperform rating.

Praxis Precision Medicines Inc. (PRAX) PT Raised to $514 at Baird

Thu, 06 Aug 2026 15:50:36 -0400

Baird analyst Brian Skorney raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $514.00 (from $400.00) while maintaining a Outperform rating.

Form 10-Q Praxis Precision Medicin For: Jun 30

Thu, 06 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26879810.html

Form 10-Q Praxis Precision Medicin For: Jun 30

Thu, 06 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26879810.html

Form 8-K Praxis Precision Medicin For: Aug 06

Thu, 06 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26879790.html

Form 8-K Praxis Precision Medicin For: Aug 06

Thu, 06 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26879790.html

Praxis Precision Medicines (PRAX) Tops Q2 EPS by 367c

Thu, 06 Aug 2026 08:20:40 -0400

Praxis Precision Medicines (NASDAQ: PRAX) reported Q2 EPS of $0.00, $3.67 better than the analyst estimate of ($3.67).

For earnings history and earnings-related data on Praxis Precision Medicines (PRAX) click here.

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and